Sphera Funds Management’s CytomX Therapeutics CTMX Stock Holding History

Sphera Funds Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.3M	Buy	879,000 +659,000	+300%	+$2.52M	0.43%	75
2026 Q1	$1.03M	Buy	+220,000	New	+$1.12M	0.16%	90
2019 Q2	–	Sell	-183,151	Closed	-$1.97M	–	96
2019 Q1	$1.97M	Sell	183,151 -90,000	-33%	-$1.33M	0.18%	86
2018 Q4	$4.13M	Buy	273,151 +40,000	+17%	+$593K	0.46%	49
2018 Q3	$4.31M	Buy	233,151 +150,009	+180%	+$3.42M	0.5%	56
2018 Q2	$1.9M	Sell	83,142 -96,858	-54%	-$2.47M	0.26%	83
2018 Q1	$5.12M	Buy	180,000 +20,000	+13%	+$571K	0.78%	38
2017 Q4	$3.38M	Sell	160,000 -50,000	-24%	-$1.04M	0.4%	62
2017 Q3	$3.82M	Buy	210,000 +10,000	+5%	+$156K	0.54%	52
2017 Q2	$3.1M	Buy	200,000 +50,000	+33%	+$754K	0.53%	56
2017 Q1	$2.59M	Buy	+150,000	New	+$1.97M	0.51%	58

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Sphera Funds Management's CTMX Position: Q2 2026 in Review

Sphera Funds Management increased its CytomX Therapeutics (CTMX) stake by 300% in Q2 2026, buying an estimated $2.52M and bringing the position to 879,000 shares worth $3.3M. The position accounts for 0.43% of the portfolio, ranked #75.

Sphera Funds Management first reported a position in CTMX in Q1 2017 and has held it in 11 quarters since. The position peaked at $5.12M in Q1 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Sphera Funds Management held 879,000 shares of CytomX Therapeutics worth $3.3M as of Q2 2026.
Sphera Funds Management bought 659,000 CytomX Therapeutics shares in Q2 2026, an estimated $2.52M.
CytomX Therapeutics made up 0.43% of Sphera Funds Management's portfolio in Q2 2026, its #75 holding.
Sphera Funds Management first reported a position in CytomX Therapeutics in Q1 2017 and has held it in 11 quarters since.
Sphera Funds Management's CytomX Therapeutics position peaked at $5.12M in Q1 2018.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.